General form of registration statement for all companies including face-amount certificate companies

Acquisition (Details Narrative) (10-K)

v3.19.3.a.u2
Acquisition (Details Narrative) (10-K) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Mar. 19, 2018
Oct. 04, 2017
Oct. 04, 2017
Jun. 30, 2018
Mar. 31, 2018
Sep. 30, 2018
Dec. 31, 2018
Sep. 30, 2019
Dec. 31, 2017
Number of shares provided in exchange for net assets     31,745,242 2,090,301 2,090,301 2,090,301    
Common stock shares issued 35,272,626           38,674,265 38,404,530 35,272,626
Common stock shares outstanding 35,272,626           38,674,265 38,404,530 35,272,626
CoNCERT Pharmaceuticals, Inc [Member]                  
Number of shares provided in exchange for net assets 2,090,301                
Percentage of common stock holdings 5.93%           6.00%    
Voting interest 6.00%                
Promet Therapeutics LLC [Member]                  
Equity ownership percentage             84.00%    
Promet Therapeutics LLC [Member] | General and Administrative [Member]                  
Acquisition-related transaction costs             $ 58,763    
Parent Company [Member]                  
Business acquisition exchange percentage   90.00%              
Number of shares provided in exchange for net assets   31,745,242              
Business acquisition acquired value   $ 1,017,342 $ 1,017,342            
Common stock shares issued             35,272,626    
Common stock shares outstanding             35,272,626    
Voting interest             90.00%